GTx Announces Removal of Full Clinical Hold By FDA for Capesaris In Advanced Prostate Cancer
GTx, Inc. announced today that the Food and Drug Administration removed its Full Clinical Hold on the Company s Investigational New Drug application for Capesaris following the review by the FDA of the Company s complete response and its new Phase II clinical protocol.

Speeding Drug Approvals [Capitol Health Call]
A bill introduced March 26 by 3 senators is intended to speed up the Food and Drug Administration's (FDA s) new medication approval process.